Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Intranasal Drug Delivery: Unravelling the Nanoparticle Formulation Puzzle
Navigate the complexities of formulating nanoparticles for intranasal drug delivery with expert insights
Dual Excipient Integration in Dry Powder Inhaler Products
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Propellant Aerosols & Transition to Low GWP pMDIs
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Primary Crystallization’s Influence on Fluticasone DPIs
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
Albuterol & Low GWP Propellants: Deposition Prediction
Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Assessing Particle Size in DPIs with Spraytec & Unidose
Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.
Simulation in In Vitro Bioequivalence for Particle Sizes
Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.
